EDITION OF FRI 25 SEP 2026
263 · BUSINESS

Merck’s remigromig meets primary endpoint in diabetic macular edema trial

publishers 5articles 5first reported 24 Sep, 12:15 UTCdeveloping since 25 Sep · 2 editions

Merck said remigromig met the primary endpoint in the pivotal Phase 2b/3 BRUNELLO study of adults with diabetic macular edema. The experimental drug is a tri-specific agonist of the Wingless-related integration site, or Wnt, pathway.

Endpoints News described the result as a first success for Merck’s return to ophthalmology. FirstWord reported that safety concerns emerged in the study.

HOW THIS STORY WAS MADE

Written from 5 articles, headlines and summaries only; 5 independent newsrooms once syndicated copies count as one; this version written within the hour the record first saw the story; the editor revised it.

Publishers
5
Source articles
5
Given to the writer
5, headlines and summaries only
Independent newsrooms
5
This version written
within the hour the record first saw the story
Second model (editor)
revised
Publication gate
passed
Human review
none

WHAT THE EDITOR DID

The second model checked the writer's draft against the same sources and changed it before publication. Struck words were in the draft; underlined words are its corrections.

WHAT IT FLAGGED editor revise: The story needs attribution for its significance claim and removal of unsupported commentary about missing details. - "The result marks a clinical success for Merck’s return to ophthalmology.": This states significance as reporting; the source material supports that Endpoints characterized it as a first success, so attribution is needed. - "FirstWord reported that safety concerns emerged in the study, but no further details were provided.": The lack of further details is commentary about the source material, not a supported reported fact.

THE DRAFT AND THE CHANGES

Merck’s remigromig meets primary endpoint in diabetic macular edema trial

Merck said remigromig met the primary endpoint in the pivotal Phase 2b/3 BRUNELLO study of adults with diabetic macular edema. The experimental drug is a tri-specific agonist of the Wingless-related integration site, or Wnt, pathway. TheEndpoints News described the result marksas a clinicalfirst success for Merck’s return to ophthalmology. FirstWord reported that safety concerns emerged in the study, but no further details were provided.study.

Written by a language model from the sources above, then checked by a second model that may only cut, attribute or correct. How it works →

OUTLETS CARRYING THE STORY, RUN BY RUN

0 2 5 26 Sep 25 Sep 12:34 UTC · Merck’s remigromig meets primary endpoint in diabetic macular edema trial

WHAT HELD, WHAT CAME LATER

From the first reports to the latest

  • Nothing ran from the first third of the coverage to the last.

Entered the story later

  • Nothing new took hold after the first third.

HOW THIS STORY DEVELOPED: EVERY HEADLINE, EVERY OUTLET →